Clinical Trials Browser

Doxorubicin × Other solid neoplasm × 90 days × Clear all

NCT05661201 2026-03-06

NEROFE and Doxorubicin in KRAS-mutated ST2-positive Solid Tumors

Phase 1 Recruiting

Other solid neoplasm

Solid Tumor